Paul Tudor Jones's CGEM Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 10,128 shares of Cullinan Therapeutics, Inc. (CGEM) worth $104,825, representing 0.00% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in CGEM for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 6,850 shares. Largest reduction occurred in Q4 2025, reducing 18,860 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Cullinan Therapeutics (CGEM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cullinan Therapeutics (CGEM) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -18,860 | Reduce 65.06% | 10,128 | $10.35 |
| Q3 2025 | +6,850 | Add 30.94% | 28,988 | $5.93 |
| Q2 2025 | +22,138 | New Buy | 22,138 | $7.53 |
Paul Tudor Jones's Cullinan Therapeutics Investment FAQs
Paul Tudor Jones first purchased Cullinan Therapeutics, Inc. (CGEM) in Q2 2025, acquiring 22,138 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Cullinan Therapeutics, Inc. (CGEM) for 3 quarters since Q2 2025.
Paul Tudor Jones's largest addition to Cullinan Therapeutics, Inc. (CGEM) was in Q2 2025, adding 22,138 shares worth $166,699.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 10,128 shares of Cullinan Therapeutics, Inc. (CGEM), valued at approximately $104,825.
As of the Q4 2025 filing, Cullinan Therapeutics, Inc. (CGEM) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Cullinan Therapeutics, Inc. (CGEM) was 28,988 shares, as reported at the end of Q3 2025.